Summary

Although aliskiren is established as an effective antihypertensive agent, it is not known whether its BP-lowering effects are dependent on baseline plasma renin activity (PRA) levels. The current prospective, open-label trial was defined to evaluate the ability of aliskiren to control BP alone and in combination with other antihypertensive medications in patients with various baseline PRA levels.